MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, WHWK had $8,834K increase in cash & cash equivalents over the period. -$97,985K in free cash flow.

Cash Flow Overview

Change in Cash
$8,834K
Free Cash flow
-$97,985K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sale of business, ...
    • Proceeds from sale of common sto...
    • Maturities of short-term investm...
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Gain on sale of business
    • Net loss
    • Others

Cash Flow
2025-12-31
Net loss
-20,596
Share-based compensation expense
9,873
Gain on sale of business
87,266
Amortization of premiums and discounts on short-term investments, net
1,527
Non-cash lease expense
74
Depreciation and amortization expense
79
Accounts receivable
1,000
Inventory
-170
Prepaid expenses and other current assets
434
Other non-current assets
438
Operating lease liabilities, net
-89
Accounts payable and accrued liabilities
3,923
Other liabilities
-202
Net cash used in operating activities
-97,433
Proceeds from sale of business, net cash, cash equivalents, and restricted cash
101,286
Purchases of property and equipment
552
Purchases of short-term investments
148,688
Maturities of short-term investments
59,845
Net cash provided by investing activities
11,891
Proceeds from sale of common stock and prefunded warrants in pipe financing
100,002
Payment of pipe financing related transaction costs
5,625
Issuance of common stock upon exercise of stock options
26
Proceeds from issuance under employee stock purchase plan
49
Deferred offering costs paid for financing
76
Net cash provided by financing activities
94,376
Net increase (decrease) in cash, cash equivalents and restricted cash
8,834
Cash, cash equivalents and restricted cash at beginning of year
28,734
Cash, cash equivalents and restricted cash at end of year
37,568
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale ofcommon stock and...$100,002K Proceeds from sale ofbusiness, net cash, cash...$101,286K Proceeds from issuanceunder employee stock...$49K Issuance of common stockupon exercise of...$26K Maturities of short-terminvestments$59,845K Net cash provided byfinancing activities$94,376K Net cash provided byinvesting activities$11,891K Canceled cashflow$5,701K Canceled cashflow$149,240K Net increase(decrease) in cash, cash...$8,834K Canceled cashflow$97,433K Payment of pipefinancing related...$5,625K Deferred offering costspaid for financing$76K Share-based compensationexpense$9,873K Accounts payable andaccrued liabilities$3,923K Inventory-$170K Depreciation andamortization expense$79K Non-cash lease expense$74K Purchases of short-terminvestments$148,688K Purchases of property andequipment$552K Net cash used inoperating activities-$97,433K Canceled cashflow$14,119K Gain on sale ofbusiness$87,266K Net loss-$20,596K Amortization of premiums anddiscounts on short-term...$1,527K Accounts receivable$1,000K Other non-currentassets$438K Prepaid expenses andother current assets$434K Other liabilities-$202K Operating leaseliabilities, net-$89K

Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics, Inc. (WHWK)